Introduction {#sec1-1}
============

Granulocyte colony-stimulating factor (G-CSF) significantly reduces the incidence of neutropenia and/or hospital stays resulting from febrile neutropenia.\[[@ref1]\] Long-acting pegylated G-CSF, such as pegfilgrastim, provides similar benefit in fewer doses.\[[@ref2]\]

High cost often impedes patient access to such products. Therefore, an affordable biologic, similar to the innovator product in terms of safety, efficacy, and structural and physicochemical properties, is required. Postmarketing surveillance (PMS) studies of biologics guide clinicians\' choice of treatment for their patients. This observational study evaluated the safety/tolerability of Peg-grafeel^™^ (Dr. Reddy\'s Laboratories Ltd., India), a pegfilgrastim approved for prophylactic treatment of chemotherapy-induced neutropenia and febrile neutropenia.\[[@ref3]\]

Methods {#sec1-2}
=======

This was a prospective, observational, multicenter, noninterventional, single-arm, open-label, PMS study conducted at 10 sites in India between May 2012 and November 2013. Patients with nonmyeloid malignancies undergoing chemotherapy, and who were prescribed Peg-grafeel^™^ as part of patient care, were eligible for this study. All eligible patients providing a written informed consent were enrolled in the study. Those patients who were on other investigational products, or had known hypersensitivity or contraindications to Peg-grafeel^™^, or were not eligible clinically were excluded from the study. The study was approved by an Institutional Review Board or an Independent Ethics Committee at each study site and was conducted in accordance with the Declaration of Helsinki, local regulations, and the International Conference on Harmonization Good Clinical Practices guidelines.

Patients received a standard dose of 6 mg Peg-grafeel^™^ in a prefilled syringe subcutaneously, approximately 24 h following their cancer-specific chemotherapy. As this was an observational study, there were no specific restrictions on the use of prior and concomitant medications. The duration of treatment with Peg-grafeel^™^ was at the physicians\' discretion based on the clinical need of each patient. Patients were discontinued from the study if they experienced a serious adverse event (SAE) or withdrew their consent.

The primary/key objective of this study was to observe the incidence of treatment-related adverse events (AEs) and SAEs in patients receiving Peg-grafeel^™^ for cancer chemotherapy-induced neutropenia and febrile neutropenia. The safety and tolerability data were recorded by the study investigators, which included treatment, treatment duration, outcomes, and causal relationship with Peg-grafeel^™^ or other suspect drugs for the observed AEs.

The data set comprised 250 patients, as defined by the inclusion criteria. The "all patients enrolled set" (ENR) comprised all patients who qualified for study inclusion, whereas the safety analysis set (SAS) comprised all patients in the ENR set who received at least one dose of Peg-grafeel^™^. The overall safety profile, based on the SAS, was summarized descriptively. AEs and SAEs were listed based on the seriousness/severity and relationship to Peg-grafeel^™^ using the World Health Organization -- Uppsala Monitoring Centre causality assessment system. All AEs were recorded with terminologies based on the Medical Dictionary for Regulatory Activities system organ classes and preferred terms, and their severity was graded as per the Common Terminology Criteria for Adverse Events (CTCAE; version 4.0).

Results {#sec1-3}
=======

A total of 250 patients (male:female = 36.4%:63.6%; median age \[range\], 54 \[16--80\] years) were enrolled in the study. Patient disposition has been depicted in [Figure 1](#F1){ref-type="fig"}. Most patients presented with Stage III (33.2%) or IV (41.6%) cancers. The most commonly observed malignancies were breast cancer, ovarian cancer, lymphomas, lung cancer, and cervical cancer. Very few patients had prior exposure to filgrastim (28%) or pegfilgrastim (26%). Demographics and baseline characteristics are presented in [Table 1](#T1){ref-type="table"}.

![Patient disposition](SAJC-6-20-g001){#F1}

###### 

Demographics and baseline characteristics

![](SAJC-6-20-g002)

A summary of therapeutic agents by international nonproprietary name is presented in [Figure 2](#F2){ref-type="fig"}. Cyclophosphamide (37.2%) and doxorubicin (31.6%) were the most commonly used chemotherapeutic agents; carboplatin (13.2%) and doxorubicin (9.6%) were the most common concomitant medications suspected to cause AEs; ondansetron (14.8%) and metoclopramide (10.8%) were the most common medications used for the management of AEs. A total of 243 (97.2%) patients received at least one concomitant medication other than the above; of these, the most common was dexamethasone (82.8%). Metformin (5.6%) and insulin (5.2%) were the most commonly used prior medications.

![Summary of chemotherapy by international nonproprietary name. \*\*Non-chemotherapeutic drug reported along with chemotherapeutic drugs in the CRF](SAJC-6-20-g003){#F2}

The total exposure to Peg-grafeel^™^ among 250 patients was 6180 mg (1030 doses), with each patient receiving an average of 24.72 mg. Based on the physicians\' discretion, the patients received at least one dose (28 \[11.2%\] patients) of Peg-grafeel^™^ to a maximum of 6 doses (72 \[28.8%\] patients). The average number of doses received by each patient was 4. A summary of the exposure to Peg-grafeel^™^ is presented in [Figure 3](#F3){ref-type="fig"}.

![Summary of exposure to Peg-grafeel™](SAJC-6-20-g004){#F3}

An overview of the AEs is presented in [Table 2](#T2){ref-type="table"}. Treatment-emergent AEs (TEAEs) were reported in 115 (46%) patients. The most commonly reported AEs were vomiting (11.6% patients), followed by pain (11.2% patients), and nausea and constipation (8.4% patients each). Neutropenia and febrile neutropenia were observed in 6 (2.4%) and 5 (2.0%) patients, respectively. Two (0.8%) patients each had Grade 4 and Grade 3 neutropenia. Grade 4 and Grade 3 febrile neutropenia were reported in 1 (0.4%) and 2 (0.8%) patients, respectively. [Table 3](#T3){ref-type="table"} shows the TEAEs occurring in ≥1% of patients, along with their severity.

###### 

Overview of adverse events

![](SAJC-6-20-g005)

###### 

Incidence of treatment-emergent adverse events occurring in ≥1% of patients by preferred term and severity

![](SAJC-6-20-g006)

A total of 13 (5.2%) patients experienced at least one Peg-grafeel^™^-related TEAE during the study. None of these were life-threatening or led to death. The most frequently reported Peg-grafeel^™^-related TEAEs were pain (3.2%), asthenia (2.4%), and arthralgia (1.2%). Peg-grafeel^™^-related back pain was reported by 2 (0.8%) patients, whereas 1 (0.4%) patient reported Peg-grafeel^™^-related pain in the extremities. [Table 4](#T4){ref-type="table"} presents a summary of Peg-grafeel^™^-related AEs based on their severity.

###### 

Incidence of Peg-grafeel^™^-related adverse events (safety population)

![](SAJC-6-20-g007)

A total of 68 SAEs were reported, with 29 (11.6%) patients reporting at least one SAE. None of the reported SAEs was considered to be related to Peg-grafeel^™^. The most commonly reported SAEs were vomiting in 7 (2.8%), pyrexia in 5 (2%), and febrile neutropenia in 5 (2.0%) patients. Neutropenia was reported as an SAE in 3 (1.2%) patients. Grade 4 thrombocytopenia was reported in 3 (1.2%) patients. SAEs led to study discontinuation in four patients (neutropenic sepsis in 1 patient, neutropenia and thrombocytopenia in 2 patients each, and pyrexia and multiorgan failure in 1 patient). A total of 5 (2%) deaths were reported during the study, none of which were related to Peg-grafeel^™^ treatment (cardiorespiratory arrest in 3 \[1.2%\] patients, abdominal pain with progression of cancer in 1 \[0.4%\] patient, and multiorgan failure in 1 \[0.4%\] patient). A list of treatment-emergent SAEs by preferred term and severity is presented in [Table 5](#T5){ref-type="table"}.

###### 

Treatment-emergent serious adverse events by preferred term (≥1% of patients) and severity (≥0.5% of patients)

![](SAJC-6-20-g008)

Discussion {#sec1-4}
==========

Patients undergoing cancer chemotherapy frequently experience hematological toxicities, neutropenia and febrile neutropenia being the most common and often most serious. Pegfilgrastim, a long-acting form of filgrastim administered as a single fixed-dose injection per chemotherapy cycle, was approved by the US Food and Drug Administration in 2002 to lower the incidence of infections manifesting as febrile neutropenia following chemotherapy for nonmyeloid malignancies.\[[@ref4]\] The high cost of pegfilgrastim has led to limited patient accessibility and underutilization in the appropriate patient population despite its advantages.\[[@ref5]\]

Peg-grafeel^™^ is a pegfilgrastim that has been approved and prescribed in India and Vietnam for reducing the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancies.\[[@ref3]\] The use of prophylactic Peg-grafeel^™^ in this study was associated with neutropenia and febrile neutropenia incidence rates of 2.4% and 2%, respectively. These rates are much lower than those reported in similar patient populations with or without prophylactic G-CSF support in India (febrile neutropenia, 15%; Grade 0--2 neutropenia, 58%; Grade 3--4 neutropenia, 42%).\[[@ref6]\] Studies conducted in other countries have shown good response to pegfilgrastim (i.e. a study in the US \[neutropenia, 2.6%; febrile neutropenia, 3.4%\]\[[@ref7]\] and Austria \[neutropenia and febrile neutropenia, 5.7%\])\[[@ref8]\] Other studies have reported greater variations in rates of febrile neutropenia (17%\[[@ref9]\] and 68.8%\[[@ref10]\]) in placebo-treated groups, largely due to differences in chemotherapeutic regimens. However, the rates of neutropenia and febrile neutropenia in this study are similar to those reported in observational studies in similar patient populations receiving pegfilgrastim prophylaxis.\[[@ref7][@ref8][@ref11]\] In one preapproval study from Dr. Reddy\'s Laboratories Ltd., CDP-03-07,\[[@ref12]\] prophylactic Peg-grafeel™ significantly reduced the duration and frequency of incidents of severe neutropenia (Grade 3 and 4) in patients with advanced nonsmall cell lung carcinoma and breast cancer; rates were comparable with Grafeel^®^ and published literature on pegfilgrastim, and distinctly different than the no-prophylaxis arm.\[[@ref13]\]

Peg-grafeel^™^ therapy was well-tolerated by a majority of patients in this study. Peg-grafeel^™^-related AEs were reported in approximately 5% patients, whereas none of the SAEs were related to the study drug. In general, the treatment-related AEs observed in this study were similar to those reported in the literature for myelosuppressive chemotherapy.\[[@ref7][@ref8][@ref11][@ref14]\]

Bone pain was reported in approximately 6--10% of patients as an AE associated with pegfilgrastim in several clinical trials.\[[@ref10][@ref14]\] A multicenter, retrospective, observational study using pegfilgrastim reported bone and muscle pain in only 1.7% of patients.\[[@ref11]\] The latter is supported by our findings, i.e. 1 (0.4%) patient reported bone pain, while 3 (1.2%) patients reported pain in the extremities. Pain was of mild or moderate severity, transient, and could be controlled with standard analgesics.

Allergic reactions/hypersensitivity including anaphylaxis, skin rash, and urticaria; generalized erythema; and flushing are listed as the side effects of pegfilgrastim.\[[@ref15]\] Treatment-emergent skin and subcutaneous tissue disorders were noted as treatment-related hypersensitivity reactions in 3.2% patients in the current PMS study. Other AEs reported in observational studies have been asthenia (2.2%), fever (0.6%), dyspnea (1.1%), anorexia (1.1%), and diarrhea (1.1%).\[[@ref11]\] In the current PMS study, \<2% patients had AEs possibly related to pegfilgrastim, such as arthralgia, malaise, back pain, leukocytosis, neutrophilia, fatigue, and pain in the extremities. None of the rare AEs associated with pegfilgrastim, such as splenic rupture, acute respiratory distress syndrome, and sickle cell crisis, were observed in the current study. None of the deaths were attributed to Peg-grafeel^™^, and no new safety concerns were identified for Peg-grafeel^™^. The safety events observed in this study are in line with the known safety profile of the originator compound pegfilgrastim.\[[@ref4]\]

There were a few limitations in this study, such as, small sample size and nonavailability of longitudinal data. Also, like all observational studies, the patients in this study had different types of cancer, and thus received varied chemotherapeutic regimens. Hence, additional studies are necessary to study the drug in larger patient populations across geographies.

Overall, this PMS study evaluated the safety and tolerability of prophylactic Peg-grafeel^™^ in patients with advanced stages of nonmyeloid malignancies in India. The safety profile of Peg-grafeel^™^ was found to be similar with that reported in the globally available literature on pegfilgrastim. It was safe and well-tolerated in patients with chemotherapy-induced neutropenia, with a low incidence of Peg-grafeel^™^-related TEAEs, no Peg-grafeel^™^-related SAEs, and no unexpected safety concerns. Thus, the potential of effective, safe, and affordable pegfilgrastim such as Peg-grafeel^™^ needs to be considered, not just to provide better accessibility to patients, but to facilitate uninterrupted cancer chemotherapy and enhance overall response, leading to a better quality of life.
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